Presseportal.ch - Ototoxicityhttps://www.presseportal.ch/de/st/Ototoxicity?langid=2Presseportal.ch: Die umfassende Schweizer Datenbank für Medieninformationen (Texte, Bilder, Grafiken, Dokumente) - ein Service der sda-Tochter news aktuell schweizde-denews aktuell schweiz AGhttps://www.presseportal.ch/images/logos/logo-ch-250.jpgPresseportal.ch - Ototoxicityhttps://www.presseportal.ch/de/st/Ototoxicity?langid=2Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced OtotoxicityAcousia Therapeutics GmbH: Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ...https://www.presseportal.ch/de/pm/100089064/100937561?langid=2Thu, 08 Jan 2026 09:01:17 +0100Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR StudyAcousia Therapeutics GmbH: Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced ...https://www.presseportal.ch/de/pm/100089064/100930916?langid=2Tue, 29 Apr 2025 09:01:33 +0200Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferencesAcousia Therapeutics GmbH: Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade ...https://www.presseportal.ch/de/pm/100089064/100922049?langid=2Mon, 12 Aug 2024 09:01:01 +0200Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New ZealandNorgine GmbH: Research Triangle Park, N.C. and Uxbridge, England (ots/PRNewswire) - Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI™, the first and only approved therapy in the European Union and U.K. for reducing ...https://www.presseportal.ch/de/pm/100053324/100917034?langid=2Mon, 18 Mar 2024 08:00:52 +0100Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-StudyAcousia Therapeutics GmbH: Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The ...https://www.presseportal.ch/de/pm/100089064/100916106?langid=2Thu, 15 Feb 2024 09:01:37 +0100Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 TrialAcousia Therapeutics GmbH: Tübingen, Germany (ots/PRNewswire) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval ...https://www.presseportal.ch/de/pm/100089064/100912152?langid=2Mon, 09 Oct 2023 11:00:57 +0200Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 TrialAcousia Therapeutics GmbH: Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the ...https://www.presseportal.ch/de/pm/100089064/100912150?langid=2Mon, 09 Oct 2023 10:00:58 +0200Hearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and SeptemberAcousia Therapeutics GmbH: Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research ...https://www.presseportal.ch/de/pm/100089064/100910472?langid=2Wed, 23 Aug 2023 10:01:57 +0200Hearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small moleculeAcousia Therapeutics GmbH: Tübingen, Germany (ots) - Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 ...https://www.presseportal.ch/de/pm/100089064/100900014?langid=2Mon, 12 Dec 2022 10:02:33 +0100Hearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11–15Acousia Therapeutics GmbH: Tübingen, Germany (ots) - Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen), will ...https://www.presseportal.ch/de/pm/100089064/100899167?langid=2Thu, 24 Nov 2022 10:02:31 +0100